|
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer Clinical research trials and Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer. Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "Q" Clinical Trials Conditions > Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer  Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
For Condition: Quality of Life,stage 2 prostate cancer,adenocarcinoma of the prostate
Status: Recruiting
Sponsor(s): American College of Surgeons , National Cancer Institute (NCI)
Synopsis: RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate-term and long-term effects of surgery and brachytherapy. PURPOSE: Randomized clinical trial to study quality of life in patients undergoing radical prostatectomy or brachytherapy for stage II prostate cancer.
Details: OBJECTIVES: - Compare changes in health-related quality of life (HRQOL) in patients with stage II prostate cancer up to 2 years after treatment with radical prostatectomy or brachytherapy. - Compare the effect of baseline HRQOL, age, and other covariates on HRQOL improvement or deterioration in these patients up to 10 years after these treatments. - Compare the effect of treatment modality on HRQOL improvement or deterioration in these patients up to 10 years after these treatments. - Compare the effects of treatment failure on HRQOL, in terms of disease progression, in these patients. OUTLINE: Patients are randomized to 1 of 2 arms on ACOSOG-Z0070 (radical prostatectomy vs brachytherapy). Patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment. PROJECTED ACCRUAL: A total of 500 patients (250 per group) will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /75 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the prostate within the past 120 days - Stage II disease (T1c-T2a, N0, M0) - Concurrent enrollment on ACOSOG-Z0070 - Not yet randomized to an intervention arm (radical prostatectomy or brachytherapy) - Willing and able to complete heath-related quality of life questionnaires PATIENT CHARACTERISTICS: Age - 75 and under Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - More than 6 months since prior hormonal therapy for prostate cancer Radiotherapy - See Disease Characteristics Surgery - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MartinSanda, Study Chair, Beth Israel Deaconess Medical Center
UCSF Comprehensive Cancer Center *Recruiting*
San Francisco, California, 94143-0128
United States
Recruiting Peter Carroll 415-353-7171
Sentara Norfolk General Hospital *Recruiting*
Norfolk, Virginia, 23507
United States
Recruiting Paul Schellhammer 757-457-5170
Fletcher Allen Health Care - Medical Center Campus *Recruiting*
Burlington, Vermont, 05401
United States
Recruiting Mark Plante 802-847-2884
Beth Israel Deaconess Medical Center *Recruiting*
Boston, Massachusetts, 02215
United States
Recruiting Martin Sanda 617-667-2960
Cleveland Clinic Taussig Cancer Center *Recruiting*
Cleveland, Ohio, 44195
United States
Recruiting Eric Klein 216-444-5591
Madigan Army Medical Center *Recruiting*
Tacoma, Washington, 98431-5048
United States
Recruiting Raymond Lance 253-968-2422
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Farhang Rabbani 646-422-4385
James P. Wilmot Cancer Center at University of Rochester Medical Center *Recruiting*
Rochester, New York, 14642
United States
Recruiting Edward Messing 716-275-3345
Washington University School of Medicine *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting Gerald Andriole 314-362-8212
Walter Reed Army Medical Center *Recruiting*
Washington D.C., District of Columbia, 20307-5000
United States
Recruiting Judd Moul 240-453-8951
Presbyterian Hospital *Recruiting*
Charlotte, North Carolina, 28233-3549
United States
Recruiting Peter Turk 704-377-3900
University Cancer Center at University of Washington Medical Center *Recruiting*
Seattle, Washington, 98195-6043
United States
Recruiting Paul Lange 206-543-3918
Holden Comprehensive Cancer Center at University of Iowa *Recruiting*
Iowa City, Iowa, 52242-1062
United States
Recruiting Kemp Kernstine 319-356-3407
Additional Information:
Study ID Numbers: CDR0000258478; ACOSOG-Z0071
Study Start Date:
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00052481
Other Stage 2 Prostate Cancer Studies:
1. Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
2. Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
3. Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
4. Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
5. SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Related Studies:
Other stage 2 prostate cancer Clinical Trials
Other North Carolina Clinical Trials
Other Charlotte Clinical Trials
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
|
|
|
|
|
|
|
|
